<DOC>
	<DOCNO>NCT01335204</DOCNO>
	<brief_summary>This Phase Ib/IIa Study Cabazitaxel plus Bavituximab patient castration-resistant prostate cancer ( CRPC ) . The current study design determine addition bavituximab cabazitaxel improve progression free survival ( PFS ) overall survival ( OS ) . In addition , Lead Researcher require collection urine , blood specimen future research . This study enroll patient CRPC , previously treat docetaxel docetaxel-containing regimen . Patients may intolerant , resistant , docetaxel , may previously treat agent without definite disease progression therapy . Patients must meet study eligibility criterion must competent give inform consent .</brief_summary>
	<brief_title>Ph Ib/IIa Study Cabazitaxel Plus Bavituximab Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>Cabazitaxel administer IV day 1 21-day treatment cycle . Bavituximab ( 3 mg/kg ) administer intravenous ( IV ) infusion weekly basis ( Cycle 1 Day 2 , cycle Day 1 ; day 8 , day 15 ) . Patients receive cabazitaxel ( day 1 ) plus bavituximab weekly 21-day cycle 8 cycle . Up 31 patient enrolled ensure 28 evaluable subject . The accrual period expect 12 18 month ( 1-1.5 year ) . Subjects remain treatment phase study follow event occur : - Disease progression evidence increase prostate-specific antigen ( PSA ) level , worsen pain , disease progression Response Evaluation Criteria Solid Tumors ( RECIST ) - Completion 8 cycle cabazitaxel-bavituximab therapy ( day 169 ) - Development toxicity , investigator 's judgment , precludes study participation - Significant protocol violation noncompliance part patient investigator - The investigator 's judgment discontinuation patient 's best interest - Initiation alternative antineoplastic treatment . - Refusal patient continue treatment follow-up - Loss follow-up After completion treatment phase , subject remain followup phase study follow event occur : - Refusal patient continue treatment follow-up - Loss follow-up - Death - The investigator 's judgment discontinuation patient 's best interest</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent obtain . Adults 18 year age old life expectancy least 3 month . Histologically confirm castrationresistant prostate cancer ( CRPC ) . Patient must demonstrate rise PSA level androgendeprivation therapy ( ADT ) nadir , least two determination four week apart . ADT define treatment Luteinizinghormonereleasing hormone ( LHRH ) agonist orchiectomy . Treatment one prior chemotherapy regimen , must contain docetaxel single agent combination agent . Patients may intolerant , resistant , cytotoxic drug combination . Patients ADT must willing continue ADT duration participation protocol . ADT initiate , ADT dose/agents may change study . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Adequate hematologic function ( absolute neutrophil count [ ANC ] ≥ 1,500 cells/μL ; hemoglobin ≥ 8 g/dL , platelet ≥ 100,000/μL ) . Adequate renal function ( serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min ) . Adequate hepatic function ( bilirubin ≤ 1.0 x upper limit normal [ ULN ] , alanine aminotransferase [ ALT ] ≤ 1.5 x ULN , aspartate aminotransferase [ AST ] ≤ 1.5 x ULN ) . Prothrombin time ( PT ) / international normalize ratio ( INR ) ≤ 1.5 × ULN . Activated partial thromboplastin ( aPTT ) time ≤ 1.5 × ULN . Prostatespecific antigen ( PSA ) level least 2 ng/mL . New York Heart Association classification I II . All patient reproductive potential must agree use approved form contraception ( determined investigator ) . Known history bleed diathesis coagulopathy ( e.g. , von Willebrand disease hemophilia ) . Any history thromboembolic event ( e.g. , deep vein thrombosis pulmonary thromboembolism ) ; central venous catheterrelated thrombosis &gt; 6 month Screening allow . Ongoing therapy oral parenteral anticoagulant ; patient lowdose anticoagulant maintain patency central venous catheter eligible . Grade 2 high peripheral neuropathy ( e.g. , numbness , tingle , and/or pain distal extremity ) . Radiotherapy ( teletherapy brachytherapy ) , chemotherapy estrogen agonist within 28 day Study Day 1 . Systemic radiotherapy ( Sm153 , Sr89 ) within 56 day study day 1 . Symptomatic clinically active brain metastasis . Major surgery within 28 day Study Day 1 . Uncontrolled intercurrent disease ( eg , diabetes , hypertension , thyroid disease ) . Any history cerebrovascular accident , transient ischemic attack time , history symptomatic coronary artery disease &lt; 6 month screen . A history condition require antiplatelet therapy ( eg , phosphodiesterase inhibitor , adenosine diphosphate receptor antagonist ) , exception general cardiovascular prophylaxis aspirin ( ≤ 325 mg/day ) . Serious nonhealing wound ( include wound heal secondary intention , ulcer , bone fracture ) . Known chronic infection human immunodeficiency virus ( HIV ) viral hepatitis . Contraindication intravenous ( IV ) contrast medium .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>JEVTANA</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Bavituximab</keyword>
</DOC>